Tempus AI Stock Price, News & Analysis

Tempus (NASDAQ: TEM) reported strong Q2 2025 financial results with revenue surging 89.6% year-over-year to $314.6 million. The company's genomics revenue grew 115.3% to $241.8 million, driven by significant volume growth in Oncology (26%) and Hereditary (32%) testing. Data and services revenue increased 35.7% to $72.8 million.

The company raised its full-year 2025 guidance to $1.26 billion in revenue and expects positive adjusted EBITDA of $5 million, marking a $110 million improvement over 2024. Tempus also completed a $750 million convertible senior notes offering at 0.75% interest rate, strengthening its financial position. The company's database now contains over 350 petabytes of clinical and molecular data, with connections to more than 40 million patient records.

Tempus AI (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, has scheduled its Q2 2025 earnings release and conference call for August 8, 2025. The earnings conference call will begin at 8:00 a.m. ET, featuring presentations from CEO Eric Lefkofsky and CFO Jim Rogers.

Investors can access the call through multiple channels, including a live audio webcast on Tempus' Investor Relations website, or by dialing (800) 715-9871 (domestic) or (646) 307-1963 (international) with Conference ID 7005219.

Tempus (NASDAQ: TEM) has received FDA 510(k) clearance for its Tempus ECG-Low EF software, an AI-powered tool designed to identify patients with low left ventricular ejection fraction (LVEF). This marks the company's second FDA-cleared ECG-AI device in its cardiovascular diagnostic portfolio.

The software analyzes 12-lead ECG recordings to detect signs of LVEF ≤40% in patients aged 40 and older who are at risk of heart failure. The technology is specifically designed for use in healthcare facilities and requires interpretation alongside other diagnostic information and clinical history.

Personalis (Nasdaq: PSNL) has expanded and extended its strategic collaboration with Tempus AI through 2029, adding colorectal cancer (CRC) as the fourth indication for their NeXT Personal® minimal residual disease (MRD) test. The test will now cover breast, lung, and colorectal cancers, plus solid tumor immunotherapy monitoring.

The expansion follows promising interim results from the VICTORI study presented at AACR 2025, showing strong performance in detecting early CRC recurrence. The collaboration leverages Tempus' extensive network reaching over 50% of U.S. oncologists to accelerate the adoption of Personalis' ultra-sensitive cancer recurrence detection technology.

Tempus AI (NASDAQ: TEM) announced the expansion of its AI-powered care pathway intelligence platform, Tempus Next, into breast cancer applications. The platform, which has already screened thousands of lung cancer patients since its 2024 launch, will now support five different biomarker testing gaps specific to breast cancer.

Mercy, with over 1,000 physician practice locations and more than 5,000 physicians, has integrated Tempus Next for both breast and lung cancer into its EMR system. The platform helps physicians stay current with evolving clinical guidelines by analyzing electronic medical records and identifying patients who may benefit from guideline-based suggestions.

Tempus AI (NASDAQ: TEM) has announced the pricing of $650 million aggregate principal amount of 0.75% Convertible Senior Notes due 2030 in a private placement, upsized from the previously announced $400 million. The company also granted an over-allotment option for an additional $100 million in notes.

The Notes will mature on July 15, 2030, with a 0.75% annual interest rate payable semiannually. The initial conversion rate is 11.8778 shares of Class A common stock per $1,000 principal amount, equivalent to a conversion price of approximately $84.19 per share, representing a 32.5% premium to the last reported sale price.

Tempus expects net proceeds of approximately $625.3 million (or $721.7 million if the over-allotment option is exercised), which will be used to repay $274.7 million of outstanding senior secured term loans, pay $36.2 million for capped call transactions, and fund general corporate purposes. The company has entered into capped call transactions to reduce potential dilution, with an initial cap price of $111.1950, representing a 75% premium over the last reported stock price.

[ "Successful upsizing of offering from $400M to $650M indicates strong investor interest", "Low interest rate of 0.75% on the convertible notes", "Net proceeds of $625.3M (potentially $721.7M with over-allotment) strengthen balance sheet", "Capped call transactions implemented to minimize potential dilution for existing shareholders", "Debt refinancing of $274.7M in senior secured term loans could improve capital structure" ]

Tempus AI (NASDAQ: TEM) has announced plans to offer $400 million in Convertible Senior Notes due 2030 through a private placement to qualified institutional buyers. The company will also grant initial purchasers an over-allotment option for an additional $60 million in notes.

The notes will be unsecured obligations maturing on July 15, 2030, with semiannual interest payments. Upon conversion, Tempus will have the flexibility to settle in cash, shares of Class A common stock, or a combination thereof. A significant portion of the proceeds will be used to repay $274.7 million in outstanding senior secured term loans.

To mitigate potential dilution, Tempus plans to enter into capped call transactions with financial institutions. These transactions are designed to reduce dilution of Class A common stock upon note conversion and/or offset cash payments exceeding the principal amount of converted notes.

Ambry Genetics, a subsidiary of Tempus AI (NASDAQ: TEM), has announced the validation of its CARE Program's accuracy in a peer-reviewed study published in the Journal of the National Comprehensive Cancer Network. The study demonstrates that CARE achieves 99.5% accuracy in interpreting NCCN Guidelines for hereditary cancer risk assessment, successfully identifying 398 out of 400 real-world patient cases.

The CARE Program is a HIPAA-compliant digital tool that integrates with electronic health records to assess patients' cancer risks through medical and family history collection. This system helps identify candidates for hereditary cancer testing and increased cancer screening, particularly important as approximately 5% of individuals have cancer predisposition gene mutations but most are unaware.

Tempus AI (NASDAQ: TEM), a technology company focused on advancing precision medicine through AI, announced its participation in TD Cowen's 4th Annual Tools/Dx Revolution Conference. The event will be held from June 22-25, 2025, in Dana Point, California. Jim Rogers, Tempus's Chief Financial Officer, will be a panelist in the session titled 'Acing AI – How To Play The Platforms' scheduled for June 23. The conference serves as a platform for discussing innovations in diagnostic tools and technologies.